These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Halpern B; Mancini MC Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121 [TBL] [Abstract][Full Text] [Related]
6. Obesity Epidemic: Pharmaceutical Weight Loss. Curry SA R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654 [TBL] [Abstract][Full Text] [Related]
7. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. Fujioka K; Braverman-Panza J J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106 [TBL] [Abstract][Full Text] [Related]
8. Topiramate and phentermine: a long story... Prescrire Int; 2013 Mar; 22(136):62. PubMed ID: 23593687 [No Abstract] [Full Text] [Related]
9. Contrave--a combination of bupropion and naltrexone for weight loss. Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849 [No Abstract] [Full Text] [Related]
10. Drug treatment of obesity. Smith SR JAMA Intern Med; 2014 Aug; 174(8):1414-5. PubMed ID: 25090179 [No Abstract] [Full Text] [Related]
12. Drug treatment of obesity--reply. Schwartz LM; Woloshin S JAMA Intern Med; 2014 Aug; 174(8):1415-6. PubMed ID: 25090180 [No Abstract] [Full Text] [Related]
13. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
14. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Bays H Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765 [TBL] [Abstract][Full Text] [Related]
15. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related]
16. Tolerability and safety of the new anti-obesity medications. Hainer V; Aldhoon-Hainerová I Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956 [TBL] [Abstract][Full Text] [Related]
17. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? Woloshin S; Schwartz LM JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599 [TBL] [Abstract][Full Text] [Related]
18. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851 [TBL] [Abstract][Full Text] [Related]
19. Phentermine plus topiramate in the treatment of obesity. Malgarini RB; Pimpinella G Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167 [No Abstract] [Full Text] [Related]
20. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Rubio MA Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595 [No Abstract] [Full Text] [Related] [Next] [New Search]